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Abstract.
Background: Cognitive decline is a frequent complication of Parkinson’s disease (PD) and the identification of predictive
biomarkers for it would help in its management.
Objective:Our aim was to analyse whether senescence markers (telomere length, p16 and p21) or their change over time could
help to better predict cognitive and motor progression of newly diagnosed PD patients. We also compared these senescence
markers to previously analysed markers of inflammation for the same purpose.
Methods: This study examined the association of blood-derived markers of cell senescence and inflammation with motor and
cognitive function over time in an incident PD cohort (the ICICLE-PD study). Participants (154 newly diagnosed PD patients
and 99 controls) underwent physical and cognitive assessments over 36 months of follow up. Mean leukocyte telomere
length and the expression of senescence markers p21 and p16 were measured at two time points (baseline and 18 months).
Additionally, we selected five inflammatory markers from existing baseline data.
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Results: We found that PD patients had shorter telomeres at baseline and 18 months compared to age-matched healthy
controls which also correlated to dementia at 36 months. Baseline p16 levels were associated with faster rates of motor
and cognitive decline over 36 months in PD cases, while a simple inflammatory summary score at baseline best predicted
cognitive score over this same time period in PD patients.
Conclusion: Our study suggests that both inflammatory and senescence markers (p16) are valuable predictors of clinical
progression in PD patients.
Keywords: Parkinson’s disease, telomere length, senescence, p16, p21, inflammation, biomarker, cognitive impairment,
dementia
INTRODUCTION
It is well established that the cumulative incidence
of dementia associated with Parkinson’s disease (PD)
is approaching 80% [1–3] and individuals with PD
are five to six times more likely to develop cognitive
impairment than age-matched controls [4]. Dementia
limits the effective medical and surgical manage-
ment of motor features of PD and is associated with
increased mortality [5], reduced quality of life [6] and
greater caregiver distress [7].
The causes for dementia in PD (PDD) are het-
erogeneous, complex and not fully understood. The
development of biological markers that could iden-
tify those at highest risk of early cognitive decline
would enhance our understanding of disease progres-
sion and give valuable insights into the underlying
pathophysiological mechanisms.
Telomeres are protective structures at chromoso-
mal ends. Telomere shortening and dysfunction cause
cellular senescence [8]. Importantly, telomeres are
susceptible to oxidative stress [9] and can be indi-
cators of ongoing disease processes in the brain. We
have previously shown that short leukocyte telom-
eres predict the development of cognitive decline and
vascular dementia in stroke patients [10]. However,
contradicting results exist regarding a possible corre-
lation between telomere length in leukocytes and PD
[11–13].
We hypothesised that accelerated telomere short-
ening in the early stages of PD may predict cognitive
decline. This is based on the findings that in indi-
viduals without dementia, performance on specific
subsets of cognitive tests correlates positively with
leukocyte telomere length [14, 15], and cognitive
decline over time is slower in subjects with longer
telomeres [16, 17]. Studies assessing the associa-
tion between blood telomere length and incident
dementia yielded variable and contradicting results
[18–20]. Similarly, for PD there are conflicting
results on the association between telomere length
and PD incidence [12, 13, 21, 22] or progression
towards cognitive decline and dementia [23–26]. A
recent meta-analysis concluded that there was no
association between leukocyte telomere length and
incidence of PD [11]. However, the relationship
between telomere length or telomere attrition rates
and the progression of motor and cognitive aspects
of PD has not been extensively investigated.
Cellular senescence is a response to stress
(including shortened or damaged telomeres) char-
acterized by an irreversible cell cycle arrest, a
pro-inflammatory secretory phenotype and a number
of not entirely specific tumour-suppressor proteins,
including the cyclin-dependent kinase inhibitors
p21CIP1Waf1 and p16INK4A [27]. A meta-analysis
of more than 300 genome wide association studies
(GWAS) identified the p16INK4a gene to be linked
to the highest number of age-associated pathologies,
including several types of cardiovascular diseases,
diabetes, glaucoma and AD [28]. Consequently, p16
and p21 have been investigated as cell senescence-
associated biomarkers of ageing [29, 30]. Brain
ageing, neurodegeneration and neuroinflammation
are associated with cellular senescence of astrocytes,
oligodendrocytes, microglia and neurons [31–34]. In
mice as well as in humans, the neuronal accumulation
of neurofibrillary tangles associated with cognitive
decline and neuronal loss in Alzheimer’s disease
causes a cellular senescence phenotype in the affected
neurons [35]. In a tau-related mouse model, specific
eradication of senescent cells improved cognition and
decreased neurodegeneration [36]. In humans, the
potential of both p16 and p21 expression as biomark-
ers of ageing and age-related diseases has previously
been explored [37–39] although not yet in the context
of PD.
A previous study on the Incidence of Cog-
nitive Impairments in Cohorts with Longitudinal
Evaluation-Parkinson’s Disease (ICICLE-PD) con-
cluded that the serum inflammatory marker profile
measured at the time of diagnosis is associated with
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subsequent rate of disease progression [40]. A pro-
inflammatory cytokine profile was associated with
more rapid motor decline as defined by changes
in UPDRS-III score over 36 months of follow-
up, as well as lower cognitive scores, whereas an
anti-inflammatory profile was associated with stable
motor function over time and better cognition [40].
Given the close inter-connection between oxidative
stress, cell senescence and inflammation as the main
drivers of the ageing process and contributors to age-
related diseases [41, 42], our aim was to determine
whether there is an association between markers of
cell senescence and cognitive and motor function in
PD patients over the first three years of their disease.
For this purpose, we analysed telomere dynamics and
senescence modulators in newly diagnosed patients
and controls from the ICICLE-PD cohort and com-
bined this with existing data on baseline inflammatory
markers to explore the relevance of these factors as
predictors of cognitive and motor impairment over
a period of 36 months from baseline. We hypothe-
sised that increased senescence and inflammation at
baseline would predict faster cognitive decline during
disease progression in the early stages of disease.
MATERIALS AND METHODS
Participants and clinical evaluation
Details of the recruitment protocol for the study
have been published [6, 43, 44]. Participants were
recruited as part of the ICICLE-PD study between
June 2009 and December 2011. They included newly
diagnosed PD patients (N = 154) from the commu-
nity and outpatient clinics, as well as unrelated age
and gender—matched control subjects (N = 99) from
Newcastle upon Tyne and Gateshead, United King-
dom. All patients fulfilled Queen Square Brain Bank
Criteria for idiopathic PD [45] and were diagnosed
by a movement disorder specialist. Global assessment
of cognitive function included the Mini-Mental State
Examination (MMSE) [46] and Montreal Cognitive
Assessment (MoCA) [47]. Exclusion criteria have
been described previously [43]. The study received
ethical approval from The Newcastle and North
Tyneside Research Ethics Committee and written
informed consent was received from all subjects.
Participants were evaluated at 18-month intervals.
At each assessment, demographic, cognitive and clin-
ical data were collected as well as blood samples. For
the clinical assessment, a semi-structured interview
collected information on areas such as symptom his-
tory, level of education and comorbid disease. Motor
severity was assessed using the Movement Disor-
der Society Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS) Part III [48] and the Hoehn and Yahr
(HY) scale [49]. Data on medication usage included
levodopa equivalent daily dose (LEDD) at the time
of recruitment [50]. Mild Cognitive Impairment (PD-
MCI) was assessed using modified MDS Level 2
criteria [51], whereby PD-MCI was classified using
1.5 SDs below normative values [44].
Blood sample collection
For inflammatory markers, venous blood samples
were collected in plain tubes, allowed to clot for
15 min at room temperature, and then centrifuged
at 2000 rpm for 15 min. Serum was removed and
stored in 200L aliquots at –80◦C until assays were
performed. For the isolation of DNA, blood sam-
ples were collected using EDTA vacutainers (Becton
Dickinson, BD Diagnostics, Oxford, UK). For the
isolation of RNA, blood samples were collected in
PAXgene Blood RNA Tubes (PreAnalytiX, Qiagen,
UK). The collection tubes were stored at –80◦C.
Nucleic acid isolation
DNA was extracted from peripheral blood
using standard phenol/chloroform techniques. DNA
sample concentration and quality was assessed
by Quant-It™Picogreen® (ThermoFisher Scientific,
USA) and stored at –80◦C.
RNA isolation was performed using the PAXgene
Blood RNA Kit (PreAnalytiX, Qiagen UK) according
to the manufacturer’s instructions. The final elution
volume was 50l and the quantity and quality of the
RNA was assessed by Nanodrop (ND-1000, Thermo
Fisher Scientific, USA) followed by storage at –80◦C.
Telomere length measurement
Telomere length (TL) was measured using a pre-
viously published quantitative PCR (qPCR) method
with modifications [52]. Briefly, the relative abun-
dance of telomeric template (T) versus a single copy
gene (36B4) (S) was estimated by PCR on 10 ng of
DNA, with 5ul SYBR®Green JumpStart Taq Ready
Mix and 0.25l of ROX reference dye (Sigma-
Aldrich, UK) and the following primers: 300 nM
TelA (5′-CGG TTT GTT TGG GTT TGG GTT TGG
GTT TGG GTT TGG GTT-3′); 900 nM TelB (5′-
GGC TTG CCT TAC CCT TAC CCT TAC CCT
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TAC CCT TAC CCT-3′) for the telomeric reaction
and 200 nM 36B4F (5′-CAG CAA GTG GGA AGG
TGT AAT CC 3′) and 400 nM 36B4R (5′-CCC ATT
CTA TCA TCA ACG GGT ACA A-3′) for 36B4. All
samples were assessed in triplicate and all PCRs were
carried out on an Applied Biosystems 7900HT Fast
Real Time PCR system with 384-well plate capac-
ity. Telomere length measurements are expressed as
T/S ratio. Three internal control DNA samples of
known telomere length (10.4 kb, 3.9 kb, and 2 kb)
were run within each plate to correct for plate-to-
plate variation. As a further authentication of our
telomere length measurements, we performed a reval-
uation of those samples that were in either the top
or bottom 5% of the telomere length distribution as
well as those samples that gave no valid data on the
first run. The intra-assay coefficient of variation was
2.7% while the inter-assay coefficient of variation
was 5.1%. DNA samples were available to perform
telomere length measurements at baseline and at 18-
month follow-up visit.
Expression of p16 and p21
The quantification of expression levels of p21
and p16 was performed by RT-qPCR analysis on an
Applied Biosystems 7900HT Fast Real Time PCR
system with 384-well plate capacity, with 500 ng of
RNA converted into cDNA by means of the qScript
cDNA synthesis kit (Quanta Biosciences, Beverley,
MA, USA) on a 20l reaction that included 1ul of
qScript reverse transcriptase. The reaction comprised
5 min at 22◦C, 30 min at 42◦C and 5 min at 85◦C.
This was followed by qPCR on p16 and p21 with
PGK1 as reference gene: the 15l reactions included
2l of cDNA, 7.5l of Applied Biosystems Power
SYBR™ Green PCR Master Mix (ThermoFisher Sci-
entific, Waltham, MA, USA) and 300 nM for both
forward and reverse primers for the respective reac-
tions: p16-1 5′-GCCCAACGCACCGAATAGTT -3′
and p16-2 5′-CACGGGTCGGGTGAGAGT -3′;
p21-F 5′-GCAGACCAGCATGACAGATTT -3′ and
p21-R 5′-GGATTAGGG CTTCCTCTTGGA -3′;
and PGK1-1 5′-TTAAAGGGAAGCGGGTCGTT
-3′ and PGK1-2 5′-GCAGCCTTAATCCT CTG-
GTTGT -3′. For each sample, all three qPCR
reactions (p21, p16 and PGK1) were performed in
triplicate and on the same plate. The thermo-cycling
programme included 10 min at 95◦C and 45 cycles
on 15s at 95◦C and 30s at 60◦C as well as a melt-
ing curve analysis. Each plate included an Internal
Control cDNA sample to correct for plate-to-plate
variations. The intra-assay %CV for the p16, p21
and PGK1 qPCR reactions were 0.60%, 0.65%, and
0.91%, respectively, while the inter-assay %CV for
the p16, p21 and PGK1 qPCR reactions were 3.80%,
2.55%, and 3.82%, respectively. Values of expression
levels for p16 and p21 were calculated by the for-
mula 2–Ct on the differences on threshold cycle
for p16 or p21 against PGK1 and for the samples
against those obtained for the internal control. RNA
samples were available to perform p21 and p16 gene
expression measurements at baseline and at 18-month
follow-up visit.
Inflammatory markers
Measurement of inflammation-related markers on
serum samples from this cohort has been previ-
ously performed and reported [40]. Briefly, markers
were measured on serum samples collected at
baseline, using MesoScale Discovery (Rockville)
electrochemiluminescent immunoassays, including
the V-PLEX human pro-inflammatory panel 1 (IFN-
, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70,
IL-13, and TNF-), and V-PLEX human CRP. All
samples were run in duplicate and as per the man-
ufacturer’s protocol [40] which yields the following
values for the inflammatory markers considered in
our analysis: Inter- assay %CVs for CRP: 7.2%;
TNF-alpha: 7.4%; IL–6:6.8%; IL–10:7.9% and IFN-
gamma: 8.2%. Intra-assay %CVs for CRP: 2.2%;
TNF-alpha: 2.4%; IL–6:3.9%; IL–10:3.1% and IFN-
gamma: 3.8%. Lower Limit of Detection for CRP:
1.33 pg/ml; TNF-alpha: 0.04 pg/ml; IL–6:0.06 pg/ml;
IL–10:0.04 pg/ml and IFN-gamma: 0.37 pg/ml. From
this existing data set, five pro-inflammatory mark-
ers (TNF-alpha, IFN-gamma, CRP, IL-6 and IL-10)
were selected because they had the strongest load-
ings on the pro-inflammatory component scores in
our previous principal component analysis (PCA)
in this ICICLE-PD dataset [40]. In this study we
sought to validate the findings of Williams-Gray et
al. [40] but through the use of a smaller number
of parameters combined into a simple compos-
ite score, which does not require a PCA-based
approach.
Statistical analyses
Statistical analyses were performed with SPSS
19.0 (SPSS, Chicago, IL). Data were examined for
normality of distribution (Shapiro-Wilk test and Q-
Q plots). Baseline characteristics are expressed as
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the median [Interquartile Range] or as percentages.
The demographic characteristics of our participants
were analysed by either an Independent samples
Mann-Whitney U test (for continuous variables)
or Pearson Chi-square test (for categorical vari-
ables). The percentage of participants for which data
were unavailable (either because the clinical infor-
mation was not acquired or because the suitable
blood samples were not collected) appear in the
column “Missing”. Because of their lack of nor-
mal distribution, data were analysed by Spearman’s
rank correlation coefficient (for correlations between
blood-related biomarkers of senescence and outcome
measures, correlations were adjusted for age, gender
and baseline LEDD) and Mann-Whitney U tests (for
comparisons between Parkinson disease and control
participants). Pearson-Chi squared tests were used
to compare categorical data. Results were consid-
ered statistically significant at a p value of <0.05 and
two-sided tests were applied.
Composite variables were calculated as detailed
below:
- Telomere length change per month:
(TL at 18 month Follow - up) − (TL at Baseline)
Interval between 18 month Follow - up and Baseline (in months)
A more negative value of this variable indicates
faster telomere shortening.
- p21 expression change per month:
(p21 Expression at 18 month Follow - up) − (p21 Expression at Baseline)
Interval between 18 month Follow - up and Baseline (in months)
A more positive value for this variable reflects a
transition to a more senescent phenotype.
- p16 expression change per month:
(p16 Expression at 18 month Follow - up) − (p16 Expression at Baseline)
Interval between 18 month Follow - up and Baseline (in months)
A more positive value for this variable reflects a
transition to a more senescent phenotype.
- Inflammatory score: it was generated from the
sum of the Z-scores for the inflammatory parame-
ters offering the most comprehensive dataset: CRP,
TNF-alpha, IL-6, IL-10 and Interferon-gamma (IFN-
gamma).
- Monthly change rate of cognitive and clinical PD
scores:
(Score at 36 months follow - up) − (Score at Baseline)
Interval between 36 months Follow - up and Baseline (in months)
For MMSE and MoCA, a more negative value rep-
resents a greater decline in cognition. Conversely,
scores for clinical features (MDS-UPDRS-III and
H&Y) increase with severity and therefore a larger
positive value of the rate of change represents a more
rapid worsening of their clinical condition. In order
to be able to identify as many significant comparisons
as possible while still maintaining a low false positive
rate we have applied the Benjamini-Hochberg multi-
ple comparisons correction with a 5% false discovery
rate.
We used Linear Regression models to assess the
relative value of our biomarker variables to predict the
changes with time (36 months) in cognitive and motor
parameters in our PD participants only. These analy-
ses were adjusted for age, gender, BMI and baseline
LEDD. We used baseline predictors of cognitive
change and therefore did not account for increase
in LEDD between baseline and 36 months in this
analysis. A previous publication from our group had
demonstrated that LEDD did significantly increase
over time, however, it was not associated with change
in cognitive scores [53].
RESULTS
Study demographics
The demographic characteristics of our study
group at baseline (99 controls and 154 PD patients)
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are described in Table 1. The table shows the study
groups were well matched for most of the demo-
graphic and clinical characteristics. The group of PD
participants presented a significantly lower alcohol
consumption, higher proportion of cases with pre-
vious history of stroke or ischaemic attack and, as
anticipated, higher presence of MCI, lower MoCA
scores and higher Geriatric Depression Scale (GDS)
scores.
Biomarkers of senescence and PD
We measured three biomarkers of cell senescence:
expression levels of p21 and p16 as well as telomere
length, at baseline, and again at 18 months, which
allowed for calculation of monthly rates of change
(Table 2).
After applying Benjamini-Hochberg correction for
multiple comparisons, PD participants had signifi-
cantly shorter telomere length at baseline compared
to controls (p < 0.001) as well as significantly faster
shortening of their telomeres over the first 18 month
period (p = 0.002) (Table 2, Fig. 1). PD participants
displayed significantly lower levels of p21 expression
than controls at baseline (p < 0.001), but there was no
difference in change with time (Table 2, Supplemen-
tary Figure 1a). For p16 expression, the differences
between PD and controls at baseline or the rate of
change per month of p16 expression levels did not
reach statistical significance (Table 2, Supplementary
Figure 1b).
Inflammatory markers at baseline and PD
We considered five inflammatory markers, both
individually and as a composite inflammatory score
(Table 2). PD participants had significantly higher
levels of TNF-alpha (p < 0.001) and IL-10 (p = 0.002)
compared to controls. Overall, the baseline composite
inflammatory score was markedly different between
both groups, with a significant difference (p < 0.001)
between PD and controls (Table 2).
Biomarkers of senescence and inflammation:
MCI at baseline
We examined whether our potential biomarkers
were associated with MCI status. For the PD group
(Table 3), of the five inflammatory markers con-
sidered, levels of CRP and IL-6 were significantly
raised (p-values 0.015 and 0.003, respectively) in
PD-MCI cases compared to those without cognitive
impairment, and the composite inflammatory score
of PD-MCI participants at baseline was significantly
higher (p = 0.006) (Table 3). We found p21 expression
levels also higher in cognitively normal participants
than in those with PD-MCI at baseline (p = 0.012). No
significant difference was found for telomere length
or p16 expression in relation to PD-MCI (Table 3).
In the case of participants from the control group, the
presence of MCI did not result in significantly differ-
ent levels of any of the senescence or inflammatory
biomarkers (data not shown).
Biomarkers of senescence and inflammation:
Dementia incidence at 36 months
Over the 36 month follow-up period, 15.5%
(N = 11) of PD patients developed PDD. These partic-
ipants had significantly shorter telomeres at baseline
and 18 months than those who did not develop PDD
(Fig. 2) but there were no significant differences for
p21, p16 or inflammatory score at baseline or 18
months follow-up (data not shown).
Biomarkers of senescence and inflammation as
predictors of cognitive and motor changes over
time
We first examined the associations between senes-
cence and inflammatory markers at baseline with
cognition (MMSE and MoCA) and motor severity
(MDS-UPDRS-III) at both baseline and 36 months
by Spearmann’s Rank correlation analysis, and found
correlations between senescence and inflammation
markers and multiple clinical variables in PD patients
(Supplementary Table 1). We analysed the predic-
tive power of baseline biomarkers further by linear
regression (Table 4). For the assessment of motor
impairment, we regarded HY scores as a binary vari-
able with a threshold of 3 (a score of 3 or above
is indicative of postural instability). We considered
both baseline, 36 months and the change between
them and tested associations of baseline biomark-
ers of senescence and inflammation to these scores
(data not shown). This was followed by a logistic
regression model to determine whether our biomark-
ers at baseline would distinguish PD participants
reaching HY stage 3 or above at the 36 month
follow-up time and/or whether they discriminated
between participants whose motor function improved
or worsened over this period of time (Table 5).
Neither TL nor p21 expression significantly pre-
dicted clinical scores or their change over 36 months
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Table 1
Baseline clinical characteristics of the study cohort
Parkinson’s Disease Controls
N = 154 N = 99
Missing Missing p
Age (Years, Median [IQR]) 67.02 [60.28,81.50] – 67.98 [63.34,82.15] –
Gender (% Women) 35.06% – 45.45% –
Body Mass Index (Median [IQR]) 26.50 [23.80,35.60] 1.30% 27.70 [24.70,34.50] 2.02%
Smoking (%Never smoked) 55.19% – 50.51% –
Age when leaving education (Years, Median [IQR]) 16.00 [15.00,25.00] – 17.00 [15.00,23.00] –
Number of units of alcohol consumed per week (Median [IQR]) 3.50 [0.00,24.00] – 6.00 [1.00,60.00] – p = 0.019a
Ischemic heart disease (%) 11.04% – 9.09% –
Type II diabetes (%) 7.79% – 5.05% –
Hypertension (%) 31.17% – 35.35% –
Hypercholesterolaemia (%) 11.69% – 20.20% –
Stroke/Transient Ischaemic Attack (%) 7.14% – 0.00% – p = 0.007b
Anti-inflammatory medication (%) 33.33% 12.34% 33.33% 6.06%
Comorbidity (CIRS System Score, Median [IQR]) 2.00 [1.00,5.00] 12.34% 3.00 [2.00,6.00] 6.06%
Mild Cognitive Impairment (%) 43.26% 8.44% 22.22% – p < 0.001b
Mini-Mental State Examination Score (Median [IQR]) 29.00 [28.00,30.00] – 29.00 [28.00,30.00] – p = 0.006a
Montreal Cognitive Assessment (Median [IQR]) 26.00 [23.00,30.00] 9.74% 27.00 [26.00,30.00] 2.02% p < 0.001a
Geriatric Depression Scale (Median [IQR]) 2.00 [1.00,8.00] – 1.00 [0.00,4.00] – p < 0.001a
National Adult Reading Test (Median [IQR]) 117.00 [108.50,127.00] 1.30% 118.00 [111.00,126.00] –
Survival at 36months Follow-up (%) 94.81% – 97.98% –
Disease Duration at Enrolment (Years, Median [IQR]) 0.39 [0.21,1.32] – – –
MDS-UPDRS-III (Median [IQR]) 26.00 [17.00,47.00] – – –
Hoehn and Yahr Score (HY) (Median [IQR]) 2.00 [2.00,3.00] – – –
Parkinson’s disease medication (%) 87.66% – – –
On Levodopa treatment (%) 29.22% – – –
Levodopa equivalent daily dose (mg/l) (Median [IQR]) 140.00 [100.00,450.00] – – –
Monoamine oxidase B inhibitors medication (%) 47.40% – – –
Dopamine agonist medication (%) 37.01% – – –
aIndependent-Samples Mann-Whitney U Test; bPearson Chi-square test.
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Table 2
Biomarkers: comparison of controls and PD patients
Parkinson’s Disease Controls
N = 154 N = 99
Median [IQR] Missing Median [IQR] Missing p
Telomere length (TL) Baseline (T/S ratio) 0.78 [0.63,0.91] 20.78% 1.03 [0.81,1.31] 22.22% p < 0.001a
TL change/month† –0.020 [–0.028,–0.013] 20.78% –0.012 [–0.023,–0.006] 22.22% p = 0.002a
p21 Baseline (A.U.) 1.16 [0.83,1.73] 6.49% 1.62 [1.01,2.43] 6.06% p < 0.001a
p21 change/month 0.002 [–0.028,0.046] 20.78% –0.006 [–0.044,0.036] 23.23%
p16 Baseline (A.U.) 1.24 [0.77,1.92] 6.49% 1.41 [0.94,1.97] 5.05%
p16 change/month 0.005 [–0.031,0.045] 20.78% –0.001 [–0.032,0.043] 23.23%
CRP (ng/ml) 1.63 [0.66,3.48] 12.34% 1.83 [0.73,3.59] 6.06%
TNF alpha (pg/ml) 2.98 [2.45,3.62] 12.34% 1.67 [1.39,2.11] 6.06% p < 0.001a
IL-6 (pg/ml) 0.64 [0.43,0.99] 13.64% 0.60 [0.42,0.81] 6.06%
IL-10 (pg/ml) 0.24 [0.17,0.35] 16.23% 0.19 [0.13,0.27] 12.12% p = 0.002a
IFNg (pg/ml) 5.92 [4.11,8.80] 12.34% 5.80 [4.32,9.03] 6.06%
Inflammatory score 0.01 [–0.84,1.26] 17.53% –1.26 [–1.85,–0.17] 12.12% p < 0.001a
aIndependent-Samples Mann-Whitney U test significant after Benjamini-Hochberg multiple test correction. †For this composite variable,
larger value = lower telomere shortening rate, see text.
Fig. 1. Telomere length at baseline and 18 months (A) and telomere shortening (given as change per months) over 18 months (B) in controls
and Parkinson’s disease patients. Each category box plot includes the median (—), the range of data within the first and third quartiles (box),
the range of data within the first and ninth deciles (whiskers) and the outliers falling outside of the latter (°). aStatistically significant using
the Mann-Whitney U Test.
(Tables 4 and 5). Paradoxically, higher p16 expression
levels at baseline predicted slower motor progres-
sion (change of MDS-UPDRS-III score) over the
next 36 months, independently of age and gender,
baseline LEDD and BMI (beta = –0.218; p = 0.0149)
(Table 4) and remained significant after adjusting
for inflammatory score (beta = –0.226; p = 0.019,
data not shown). In addition, higher p16 expres-
sion levels at baseline predicted slower cognitive
decline (MoCA score change rate) over 36 months,
independently of age, gender, baseline LEDD and
BMI (beta = 0.311; p = 0.003) (Table 4). This asso-
ciation again remained significant after adjusting
for inflammation (beta = 0.399; p < 0.001, data not
shown).
The baseline composite inflammatory score was
only predictive of MoCA score (beta = –0.205,
p = 0.037) at 36 months (Table 4), independently of
age, gender, BMI and LEDD, but not for the rate of
change for any clinical indicator over the follow-up
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Table 3
Biomarkers and MCI at baseline in PD participants
Cognitively Normal MCI at Baseline
N = 80 N = 61 p
Median [IQR] Missing Median [IQR] Missing
TL Baseline (T/S ratio) 0.77 [0.58,0.90] 21.25% 0.79 [0.64,0.93] 22.95%
p21 Baseline (A.U.) 1.34 [0.93,1.98] 6.25% 1.03 [0.74,1.49] 4.92% p = 0.012a
p16 Baseline (A.U.) 1.14 [0.74,1.74] 6.25% 1.29 [0.77,1.80] 4.92%
CRP (ng/ml) 1.10 [0.41,2.85] 12.50% 2.20 [0.82,5.26] 14.75% p = 0.015a
TNF alpha (pg/ml) 2.74 [2.21,3.41] 12.50% 3.25 [2.51,3.78] 14.75%
IL-6 (pg/ml) 0.58 [0.36,0.87] 15.00% 0.78 [0.58,1.34] 14.75% p = 0.003a
IL-10 (pg/ml) 0.23 [0.17,0.35] 17.50% 0.26 [0.17,0.39] 16.39%
IFNg (pg/ml) 5.78 [4.18,8.04] 12.50% 6.46 [4.88,11.23] 14.75%
Inflammatory score –0.27 [–0.89,0.54] 20.00% 0.51 [–0.44,2.24] 16.39% p = 0.006a
aIndependent-Samples Mann-Whitney U test significant after Benjamini-Hochberg multiple test correction.
†For this composite variable, larger value = lower telomere shortening rate, see text.
Fig. 2. Biomarkers and development of dementia in PD. A) Telomere length at baseline and its relationship to PD dementia at 36 months.
B) Telomere length at 18 month follow-up and its relationship to PD dementia at 36 months. C) Telomere length shortening per month and
its relationship to PD dementia at 36 months. Each category box plot includes the median ( —), the range of data within the first and third
quartiles (box), the range of data within the first and ninth deciles (whiskers) and the outliers falling outside the latter (° = Outlier, ∗ = Extreme
Outlier). aStatistically significant using the Mann-Whitney U Test.
period. None of our candidate baseline biomarkers of
senescence and inflammation significantly predicted
MMSE score (Table 4) or motor function (Table 5)
either at 36 months or as rate of change over 36
months.
DISCUSSION
This study included newly diagnosed PD patients
at a very early stage of disease, and an age matched
control cohort, who were followed up every 18
months to 36 months, and where we had baseline
measures of senescence and inflammation. We con-
sidered several markers that have been associated
with ageing and cellular senescence including telom-
ere length, p21 and p16 expression levels as well as
markers of inflammation. Our aim was to test the
hypothesis that increased senescence and inflamma-
tion at baseline would drive a faster cognitive and
motor decline.
Senescence markers
We measured the association of three potential
markers of cell senescence—telomere length, p16
and p21 expression in peripheral blood mononuclear
cells (PBMCs) with PD status and progression. We
found that telomere length at baseline discriminated
well between PD patients and age-matched controls,
in line with some previous cross-sectional studies
[21–23, 25], but conflicting with others [12, 13, 24,
26]. A previous meta-analysis suggested no telom-
ere length differences overall, although there were
large discrepancies on size and gender distributions
of the cohorts included as well as in the types of
tissues sampled [11]. Nevertheless, we also showed
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Table 4
Linear regression modelling on biomarkers and disease progression in Parkinson’s disease participants∗
Baseline Biomarkers TL (T/S ratio) p21 expression (A.U.) p16 expression (A.U.) Inflammatory Score
Beta p value Beta p value Beta p value Beta p value
MDS-UPDRS-III at 36 months –0.068 0.477 0.021 0.811 –0.175 0.051 0.174 0.079
change rate over 36 months –0.020 0.832 0.110 0.216 –0.218 0.014 –0.004 0.970
MMSE at 36 months 0.149 0.134 –0.009 0.922 0.080 0.409 –0.068 0.512
change rate over 36 months 0.043 0.682 –0.031 0.751 0.120 0.231 0.116 0.287
MoCA at 36 months 0.106 0.262 0.008 0.934 0.080 0.389 –0.205 0.037
change rate over 36 months 0.066 0.560 –0.070 0.516 0.311 0.003 0.055 0.653
∗All models adjusted for age, gender, baseline LEDD and BMI.
Table 5
Logistic Regression modelling on biomarkers and motor impairment (HY 3 or above) at 36 months follow-up
Baseline Biomarkers TL (T/S ratio) p21 expression (A.U.) p16 expression (A.U.) Inflammatory Score
O.R. p value O.R. p value O.R. p value O.R. p value
Motor Impairment at 36 monthsa 0.217 0.273 1.000 0.698 0.988 0.831 1.006 0.939
Change over 36 monthsb Motor Improvement 0.383 0.534 0.415 0.171 0.995 0.805 1.086 0.367
Motor Impairment 0.535 0.748 1.000 0.941 0.471 0.288 1.110 0.374
O.R., Odds Ratio; aBinary Logistic Regression. bMultinomial Logistic Regression. Reference category: No Change from Baseline to 36 months follow-up; Motor Improvement: from HY ≥ 3 to
HY < 3; Motor Impairment: from HY < 3 to HY ≥ 3. All models adjusted for age, gender, baseline LEDD and BMI.
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a similar difference at 18 months follow-up, with
faster rates of telomere shortening in PD participants.
This is in contrast to a recent study [23] that did not
find different telomere attrition rates between base-
line and 36 months for controls and PD patients.
While both PD cohorts were very similar in terms
of HY and MDS-UDPRS-III scores at baseline, our
cohort was slightly younger (about 3 years), with
shorter disease duration at baseline and, importantly,
larger. Importantly, we found shorter telomeres at
baseline in those PD patients who went on to develop
an early dementia. These patients showed no dif-
ferences in p21 or p16 gene expression levels, or
inflammatory score compared to those who did not
develop dementia. Unfortunately, the small number
of incident PDD cases in our study precluded a mean-
ingful regression analysis of the predictive power of
telomere length for PDD. However, the relationship
between shorter telomeres in peripheral blood cells
and incident dementia has been reported in the gen-
eral population [19], in stroke [10], AD [54, 55],
Down’s syndrome [56] and in the transition from MCI
to dementia [57]. Consequently, our results suggest
that short telomeres may have predictive potential for
the development of PDD.
Our results for p21 and p16 were less in line with
expectations. The known role of p21 and p16 in cell
senescence suggested their relevance as biomarkers
of ageing [37, 58]. However, there are few studies
on their links to human neurodegeneration [59]. It
has been shown previously that p16 in brain neurons
and astrocytes increases with ageing and neurode-
generation in mice and that various other senescence
markers increase in neurons of ageing mice [33,
36]. Importantly, eradication of senescent cells in a
mouse model for PD resulted in better motor function,
suggesting a therapeutic benefit [60]. In addition,
regional PD-specific white matter alterations have
been correlated with increased peripheral leukocyte
apoptosis and systemic inflammation [61].
However, we found no significant differences
between PD and controls for p16 expression at any
time point and, contrary to expectations, a lower p21
expression level in PD patients at baseline compared
to controls. Moreover, PD patients who presented
with MCI at recruitment had lower p21 baseline
expression levels than those who were cognitively
normal. Similarly, low levels of p16 at baseline were
robustly associated with faster disease progression.
These observations add to existing evidence sug-
gesting that the association of senescence of blood
cells with neurodegenerative diseases might not be
as simple as originally thought. In particular, our
own previous immuno-phenotyping studies showed a
reduction of ‘late senescent’ CD8+ T cells (identified
as CD28loCD57hi) in PD cases versus controls [62].
Furthermore, in AD patients monocytic p21 protein
levels were decreased compared to control individu-
als [59]. Hence it is possible that a more activated,
less senescent immune system might contribute to
neurodegeneration.
This study was limited in terms of available sam-
ples such that we were not able to measure protein
levels in PBMCs. A previous small study of p21
protein levels in PBMCs did not find significant
differences between PD patients and controls for
either total p21 protein or its phosphorylated form
p21(Thr145) [63]. However, the authors found that
phosphorylated Ser15 p53 and Thr145- phosphory-
lated p21 proteins were significantly increased in
blood samples from 10 AD cases compared to con-
trols. Thus, it is possible that only phosphorylated
p21 is increased during certain neurodegenerative
diseases, while total p21 protein levels, and perhaps
p21 gene expression levels, may be less informative.
In addition, p16 (and by extension, p21) mRNA lev-
els in total white blood cells might not be sensitive
enough: alterations may only be detectable in sepa-
rated T lymphocyte populations [64] but we did not
have the appropriate samples to investigate this.
Inflammatory markers
We created a simple (baseline) inflammatory score
as a summary variable reflecting the inflammatory
status of our participants. This score was significantly
higher in PD cases than in controls in agreement with
previous results using a principal component anal-
ysis within the ICICLE-PD study extended cohort
[40] and by others analysing individual markers [61,
65]. Furthermore, our inflammatory score in PD cases
at baseline correlated negatively with both cognitive
parameters (MMSE and MoCA) and positively with
the motor function MDS-UPDRS-III scores at base-
line. It was also a significant predictor of both motor
(MDS-UPDRS-III) and cognitive (MoCA) function
in PD cases at 36-months, in line with a previous
study [40]. A very similar composite inflammatory
score including TNF-alpha, IL-6 and CRP has already
shown to be, after age, the main predictor of cog-
nitive function for those aged over 75 years [52].
Given the wide disparity between studies on individ-
ual cytokines [66, 67], such composite variables may
offer a more informative evaluation of disease pro-
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gression in PD [65] and the anti-inflammatory effect
of potential treatments [68].
In summary, our study demonstrates that telomere
lengths at baseline and 18 months were lower in PD
patients compared to age-matched healthy controls
with shorter telomere length at baseline and at 18
months also associated with development of demen-
tia within 36 months. A baseline inflammatory score
consisting of five different cytokines gave the best
prediction for cognitive scores of PD cases 3 years
later, while lower p16 gene expression predicted a
more rapid disease progression over the same period
in relation to both cognitive and motor scores. Thus,
both inflammatory and senescence markers (telom-
ere length and p16) warrant further investigation as
potential predictors of disease progression in PD.
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